Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668880 | 0.87 | L3MBTL1 (0.33) | MAPTALDH1A1POLBLMNATSHR | |
| SCHEMBL2971503 | 0.86 | L3MBTL1 (0.34) | RAB9AMAPTALDH1A1POLBLMNA | |
| SCHEMBL2969663 | 0.85 | L3MBTL1 (0.33) | MAPTALDH1A1POLBLMNATSHR | |
| SCHEMBL2668689 | 0.84 | L3MBTL1 (0.32) | MAPTALDH1A1POLBLMNATSHR | |
| SCHEMBL13204383 | 0.84 | MAPK1 (0.35) | MAPTALDH1A1POLBGAALMNA | |
| SCHEMBL3499830 | 0.80 | L3MBTL1 (0.32) | MAPTALDH1A1POLBLMNAL3MBTL1 | |
| SCHEMBL2659545 | 0.79 | CNR1 (0.33) | — | |
| SCHEMBL2659944 | 0.78 | LMNA (0.33) | RAB9AMAPTALDH1A1POLBGAA | |
| SCHEMBL2962036 | 0.78 | KDM4E (0.31) | ALDH1A1TSHRKDM4E | |
| SCHEMBL3500924 | 0.77 | LMNA (0.31) | RAB9AMAPTALDH1A1LMNAPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144702-A1 | INDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144702-A1 | INDOLE COMPOUND | GCKR, GPR119, SLC5A1 | RAB9A 3121/4885LIMK2 2916/4885MAPT 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.